-
HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023
•
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the six months ended June 30, 2023, along with updates on key clinical and commercial developments. The company reported a significant increase in total revenues, which jumped by 164% (173% at constant exchange rate) to USD…
-
Shanghai HSA Unveils Measures to Boost Access to Innovative Drugs and Devices
•
The Healthcare Security Administration (HSA) in Shanghai has recently released a set of Measures aimed at “Further Improving the Diversified Payment Mechanism and Supporting the Development of Innovative Drugs and Devices.” These Measures are designed to enhance Basic Medical Insurance (BMI) policies, strengthen commercial health insurance, and establish a multi-party…
-
Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results
•
Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023, marking the company’s first period of positive earnings. The firm expects to achieve profits of RMB 2.3 billion (USD 321.8 million) during this period. Contributing Factors to Positive EarningsThe positive earnings are attributed to several…
-
MicroPort MedBot’s SkyWalker Orthopedic Surgery Robot Gains TGA Approval in Australia
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing approval from the Therapeutic Goods Administration (TGA) in Australia for its in-house developed orthopedic surgery robot, SkyWalker. This marks another significant milestone for the company as it expands the global footprint of its innovative medical…
-
CDE Releases Draft Guidelines for Clinical Pharmacology Research of Chemical Modified Drugs
•
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Pharmacological Research of Chemical Modified Drugs (draft proposal)”, which is now open for public comment for a period of one month. The aim of these guidelines is to clarify the clinical pharmacological characteristics and overall considerations of…
-
Baidu Health Partners with GSK for Shingles Disease Education Programs in China
•
China Internet giant Baidu’s Health Internet Hospital unit has entered into a strategic partnership with UK pharmaceutical major GlaxoSmithKline plc (GSK, NYSE: GSK). The collaboration aims to leverage GSK’s medical science expertise and Baidu Health’s science and technology capabilities to execute various disease education programs, with a primary focus on…
-
Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density
•
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a Phase II clinical study. The study will assess the safety, tolerability, and pharmacokinetics of its drug TST002 (blosozumab) in Chinese patients with decreased bone density.…
-
Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its pipeline candidate, ZG006. The molecule is set to enter trials targeting general advanced solid tumors. ZG006: A Pioneering Tri-Specific AntibodyZG006 is…
